Bajcsy-Zsilinszky Kórház és Rendelőintézet, Budapest Summary The care of diabetic patients often needs tight collaboration between diabetologists and other medical specialists.
Due to the cardiovascular complications of patients with type 2 diabetes the consultations between cardiologists and diabetologists are of great importance during the treatment. The recently completed cardiovascular safety trials with novel, innovative antihyperglycaemic drugs provided important information for both cardiologists and diabetologists.
Nevertheless, the increased risk of hospitalization for heart failure in SAVOR with saxagliptin was not expected. Based on the results of cardiovascular safety trials, the preference of antihyperglycaemic drugs with cardiovascular benefits in Hungary at empagliflozine, liraglutide for treating type 2 diabetic patients was emphasized in several updated clinical guidelines.
The novelties of these studies also highlighted the importance of collaboration between diabetologists and cardiologists. All rights reserved.
The content on this site is intended for health professionals.